Brief: Lumiradx Reports Fourth Quarter And Full Year 2022 Results
March 21 (Reuters) - Lumiradx Ltd LMDX.O :
* LUMIRADX REPORTS FOURTH QUARTER AND FULL YEAR 2022 RESULTS
* QTRLY LOSS PER SHARE $0.32
* RECORDED AN ACCOUNTING IMPAIRMENT OF $96 MILLION IN Q4 OF
2022
FOR EXCESS MANUFACTURING AND INVENTORY RELATED TO AMIRA COVID
TESTS
* Q4 2022 REVENUE OF $41.1 MILLION COMPARED TO Q4 2021
REVENUE OF
$118.3 MILLION
* Q4 EARNINGS PER SHARE VIEW $-0.20, REVENUE VIEW $41.7
MILLION --
REFINITIV IBES DATA
Source text for Eikon: ID:nGNX7sWQ9f
Further company coverage: LMDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing